Welcome to our dedicated page for Airsculpt Technologies news (Ticker: AIRS), a resource for investors and traders seeking the latest updates and insights on Airsculpt Technologies stock.
About AirSculpt Technologies, Inc.
AirSculpt Technologies, Inc. (NASDAQ: AIRS) is a leading provider of premium body contouring procedures, operating under its exclusive brand, Elite Body Sculpture. The company specializes in delivering minimally invasive fat removal and body sculpting treatments using its patented AirSculpt® technology. Designed to optimize precision and patient comfort, the AirSculpt® procedure offers a modern alternative to traditional liposuction by combining fat removal and skin tightening in a single treatment. This innovative approach allows for faster healing, minimal bruising, and natural-looking results, catering to patients seeking advanced aesthetic solutions.
Business Model and Operations
AirSculpt operates a direct-to-consumer business model, with revenue generated through elective medical procedures performed at its dedicated clinics. The company employs an asset-light business strategy, focusing on operating premium centers equipped with state-of-the-art technology. Each location is designed to enhance the patient experience, providing a luxurious and comfortable environment. Currently, AirSculpt has expanded its presence to over 30 locations across the United States, Canada, and the United Kingdom, with plans for continued growth in response to increasing consumer demand for its services.
Proprietary Technology and Differentiation
At the core of AirSculpt's value proposition is its proprietary AirSculpt® technology, a minimally invasive fat removal method that uses a patented technique to remove unwanted fat while simultaneously tightening the skin. Unlike traditional liposuction, AirSculpt requires no general anesthesia, reduces trauma to surrounding tissues, and enables quicker recovery times. The company has also developed complementary procedures, such as AirSculpt®+ skin tightening and AirSculpt® Lift, which further enhance its offerings by addressing skin laxity and facial rejuvenation.
Market Position and Industry Context
AirSculpt Technologies operates within the growing aesthetics and body contouring market, a sector driven by rising consumer interest in minimally invasive cosmetic procedures. The company's unique technology and premium branding position it as a key player in this space, competing with both surgical and non-surgical alternatives. Its focus on delivering consistent, high-quality results has contributed to a strong reputation among patients, with more than 70,000 procedures successfully performed since its inception in 2012.
Challenges and Competitive Landscape
While AirSculpt benefits from a differentiated product offering and growing market demand, it faces competition from traditional liposuction providers and emerging non-invasive technologies such as CoolSculpting and laser-based fat reduction methods. Additionally, the elective nature of its procedures makes it sensitive to economic fluctuations. To mitigate these challenges, the company emphasizes innovation, operational efficiency, and strategic location expansion to capture a larger share of the addressable market.
Future Outlook
AirSculpt Technologies is well-positioned to capitalize on the increasing demand for aesthetic procedures. With a focus on expanding its clinic network, enhancing operational efficiencies, and leveraging its proprietary technology, the company aims to drive long-term growth and profitability. Its commitment to delivering exceptional patient outcomes and maintaining a strong brand presence underscores its potential for continued success in the competitive body contouring market.
AirSculpt Technologies (NASDAQ: AIRS) has updated its fiscal year 2024 guidance, lowering expectations from previous projections. The company now anticipates revenues of approximately $180.0 million, down from the previous guidance of $183-189 million, and Adjusted EBITDA of approximately $20.5 million, reduced from the previous $23-28 million range.
New CEO Yogi Jashnani, who recently started his position, outlined plans to stabilize revenue and return to growth by implementing business process changes and enhancing technology usage. The company, which has performed over 70,000 procedures across 32 global centers, aims to leverage its proprietary technology and asset-light business model for long-term profitable growth.
AirSculpt Technologies (NASDAQ: AIRS), a premium body contouring procedures provider, has announced its participation in the upcoming ICR Conference 2025 at The Grande Lakes Orlando in Florida. The event will take place from January 13-14, 2025.
CEO Yogi Jashnani and CFO Dennis Dean will conduct investor meetings and deliver a presentation on January 14, 2025, at 10:00 a.m. EST. The presentation will be accessible via live webcast on the company's investor relations website, with the recording remaining available for 90 days.
AirSculpt Technologies (NASDAQ:AIRS) has appointed Yogi Jashnani as Chief Executive Officer and Board member, effective January 7, 2025. Jashnani succeeds Interim CEO Dennis Dean, who will continue as Chief Financial Officer. With over two decades of experience, Jashnani joins from Sky Zone where he served as Chief Revenue Officer.
Previously, as Chief Commercial Officer at Ideal Image, Jashnani drove growth through loyalty programs and new services. His experience includes executive roles at Advance Auto Parts, where he doubled eCommerce revenue, and Capital One Financial Services. The appointment aims to capitalize on AirSculpt's market position in premium body contouring procedures.
Jashnani's priorities will focus on accelerating same-center sales growth, enhancing operational efficiencies, and maximizing the potential of the AirSculpt method.
AirSculpt Technologies (NASDAQ: AIRS) has announced the opening of its new body contouring center in White Plains, NY, marking its 32nd location. The new facility features three operating rooms for simultaneous procedures and offers the AirSculpt+ skin tightening procedure. This expansion represents the company's second location in New York, responding to growing market demand. The AirSculpt+ procedure combines fat removal with Renuvion® technology, using helium gas and radiofrequency energy for skin tightening. Since 2012, over 60,000 AirSculpt procedures have been performed across their locations in the U.S., Canada, and the United Kingdom.
AirSculpt Technologies (NASDAQ:AIRS) reported Q3 2024 results with revenue of $42.5 million, representing a 9.1% decline from Q3 2023. The company posted a net loss of $6.0 million and Adjusted EBITDA of $4.7 million. Case volume decreased 4.3% to 3,277 cases. Despite challenges in the consumer environment, the company opened four new centers during the quarter. For the first nine months of 2024, revenue declined 4.8% to $141.2 million. The company affirmed its 2024 guidance with revenue expected between $183-189 million and Adjusted EBITDA between $23-28 million.
AirSculpt® Technologies, Inc. (NASDAQ: AIRS), a leader in premium body contouring procedures, has opened a new center in Birmingham, MI, increasing its total locations to 31. The center, located at 555 S. Old Woodward Avenue Suite 500, features two operating rooms for concurrent procedures and offers the popular AirSculpt®+ skin tightening procedure.
Dennis Dean, Interim CEO, expressed excitement about introducing AirSculpt's exclusive technology to Birmingham. The clinic is situated on the main strip, surrounded by upscale retail shops. AirSculpt®+ combines AirSculpt® fat removal with Renuvion® treatment, using helium gas and radiofrequency energy to tighten skin and improve laxity.
Since 2012, over 60,000 AirSculpt® cases have been performed across the company's locations in the U.S., Canada, and the United Kingdom.
AirSculpt® Technologies, Inc. (NASDAQ: AIRS), a leading provider of premium body contouring procedures, has announced the opening of a new center in Deerfield, IL. This expansion brings the company's total location count to 30. The new center, located at 720 Waukegan Rd Suite 200, features three operating rooms and offers the popular AirSculpt®+ skin tightening procedure.
Dennis Dean, Interim CEO, expressed excitement about bringing AirSculpt's proprietary technology to Deerfield, citing strong demand in their existing Chicago clinic. The AirSculpt®+ procedure combines AirSculpt® fat removal with Renuvion® skin tightening technology, offering patients a comprehensive body contouring solution.
Since 2012, AirSculpt® has performed over 60,000 cases across its locations in the U.S., Canada, and the United Kingdom. The company continues to expand its presence to meet growing market demand for premium body contouring services.
AirSculpt® Technologies, Inc. (NASDAQ: AIRS), a leader in premium body contouring, has opened its 29th center in Columbus, OH. The new facility, located at 4100 Regent St Suite 4-H in Easton Town Center, features two operating rooms for concurrent procedures. The center also offers the popular AirSculpt®+ skin tightening procedure, which combines AirSculpt® fat removal with Renuvion® technology for improved skin laxity. This minimally invasive treatment uses helium gas and radiofrequency energy to create a plasma that corrects sagging skin and restores a youthful appearance. Since 2012, AirSculpt® has performed over 60,000 cases across its locations in the U.S., Canada, and the United Kingdom.
AirSculpt Technologies (NASDAQ:AIRS) reported Q2 2024 results with revenue of $51.0 million, a net loss of $3.2 million, and Adjusted EBITDA of $6.9 million. The company faced challenges due to a difficult consumer spending environment and increased brand awareness spend. Key points include:
- Case volume declined 5.7% to 3,949
- Revenue decreased 8.4% year-over-year
- Net loss of $3.2 million compared to $1.8 million net income in Q2 2023
- Adjusted EBITDA of $6.9 million, down from $14.6 million in Q2 2023
AirSculpt revised its 2024 guidance, projecting revenues of $180-$190 million and Adjusted EBITDA of $23-$28 million. The company plans to open five new centers in H2 2024. Dennis Dean has been appointed Interim CEO following Todd Magazine's resignation.
AirSculpt Technologies, Inc. (NASDAQ:AIRS), a national provider of premium body contouring procedures, has announced significant leadership changes. Todd Magazine has stepped down as Chief Executive Officer and Board member, transitioning to an advisory role until December 31, 2024. Dennis Dean, the company's Chief Financial Officer, has been appointed as interim CEO while a search for a permanent successor is conducted.
Dr. Aaron Rollins, Executive Chairman, expressed confidence in the company's business model and growth potential. The focus will be on core body contouring procedures, reducing long-term marketing spend, and increasing fiscal discipline in response to the current economic environment. Dennis Dean emphasized the company's plan to focus on core operations, reduce expenses, and position for efficient scaling to deliver consistent revenue growth with industry-leading EBITDA margins as conditions improve.
FAQ
What is the current stock price of Airsculpt Technologies (AIRS)?
What is the market cap of Airsculpt Technologies (AIRS)?
What is AirSculpt Technologies, Inc.?
How does AirSculpt® technology differ from traditional liposuction?
How does AirSculpt Technologies generate revenue?
What is the competitive advantage of AirSculpt Technologies?
What are the main challenges AirSculpt Technologies faces?
Where are AirSculpt clinics located?
What additional procedures does AirSculpt offer?
Who are AirSculpt Technologies' competitors?
What is the company's growth strategy?
What is the market outlook for body contouring procedures?
